Merck to deliver 3.1 million treatment courses of COVID anitviral.
who are more likely to become seriously ill -- mainly people 65 and older or people who have chronic illnesses such as heart disease, lung disease, diabetes, obesity, or compromised immune systems.
Both antivirals require a five-day course of treatment. Merck’s is for adults ages 18 and older, and Pfizer’s for anyone age 12 and up. In clinical trials, molnupiravir reduced the risk of hospitalization or death in Covid patients by 30% but slashed the risk of dying by 90%, Davis said. “The fact that molnupiravir does reduce the risk of death by 90%, we could have a meaningful impact in helping patients,” he said.
Davis told CNBC that Merck sold $952 million in molnupiravir pills in the fourth quarter and is on track to rack up an extra $5 billion to $6 billion in sales in 2022.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
COVID-19 live updates: Santa Clara Co. approves extra vaccine dose for immunocompromisedTransplant recipients, cancer patients and people with immunodeficiencies can now receive a third dose of the Moderna or Pfizer vaccine in Santa Clara County.
Baca lebih lajut »
Through COVID haze, Alaska’s Olympic contingent eyes medals in BeijingThe 49th state is sending curlers, cross-country skiers, a figure skater and a hockey player in search of new hardware in Beijing.
Baca lebih lajut »
COVID tests, isolation hotels and a burner phone: An ADN reporter’s trip to BeijingNat Herz’s trip to China to cover the Olympic Games is a reporting trip unlike any other he’s been on.
Baca lebih lajut »
When can children younger than 5 get vaccinated against Covid-19?Children younger than 5 in the United States could begin receiving Covid-19 vaccinations this month or next if the US Food and Drug Administration moves quickly to authorize the shot for this age group.
Baca lebih lajut »